Blunted Post-COVID-19 Humoral Immunity in Patients With CNS Demyelinating Disorders on Anti-CD20 Treatments
With unclear characteristics of post-infection and post-vaccination immunity, the multiple sclerosis community lacks evidence to guide patients on their continued coronavirus disease 2019 Food Toppers (COVID-19) infection risk.As disease modifying treatments all modulate the immune system, we expect their use to alter acquired immunity to COVID-19,